Skip to main content
. Author manuscript; available in PMC: 2018 Feb 9.
Published in final edited form as: Cell. 2017 Feb 9;168(4):724–740. doi: 10.1016/j.cell.2017.01.016

Figure 2. Platforms for Redirecting T Cells to Cancer.

Figure 2

(A) T cell receptors (e.g., anti-NY-ESOI) or chimeric antigen receptors (e.g., anti-CD19 CAR).

(B) CAR structure includes an extracellular antigen recognition domain fused to intracellular TCR signaling domains (CD3z) and co-stimulatory domains (e.g., CD28 or 4-1BB).

(C) Current status of CD19 CAR therapies.

(D) Current status of engineered T cells directed toward solid tumors.